3388-79-2

Basic information

• Product Name: 2-PIPERAZIN-2-YL-ETHANOL
• Synonyms: 2-PIPERAZIN-2-YL-ETHANOL-2HCl;2-(Piperazin-2-yl)ethanol dihydrochloride;2-piperazineethanol dihydrochloride;2-hydroxyethyl dihydrogenphosphate;Aethylenglykol-monophosphorsaeure;Ethylene glycol,monophosphated
• CAS NO: 3388-79-2
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.19
• Mol File: 3388-79-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 270.4±20.0 °C(Predicted)
• Appearance: /
• Density: 0.974±0.06 g/cm3(Predicted)
• PKA: 15.11±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERAZIN-2-YL-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-2-YL-ETHANOL(3388-79-2)
• EPA Substance Registry System: 2-PIPERAZIN-2-YL-ETHANOL(3388-79-2)

Safety Data

• Hazardous Substances Data: 3388-79-2(Hazardous Substances Data)

Usage

General Description

2-PIPERAZIN-2-YL-ETHANOL is a chemical compound with the molecular formula C6H14N2O. It is a derivative of piperazine and is commonly used in the synthesis of pharmaceuticals and organic compounds. The compound is known for its vasodilatory and cardiovascular effects, making it useful in the treatment of various medical conditions. 2-PIPERAZIN-2-YL-ETHANOL is also used as a solvent for various substances and as an additive in cosmetic and personal care products. It is important to handle this compound with care as it may have harmful effects if not used properly.

Upstream product

• 1404504-29-5 4-chloro-3,5-diphenyl-1H-pyrazolo[3,4-c] pyridazine 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 
• 109-08-0 2-Methylpyrazine 
• 89852-17-5 methyl 2-(3-oxopiperazin-2-yl)acetate 
• 6705-31-3 2-(2-hydroxyethyl)-pyrazine 
• 33422-35-4 ethyl 2-(3-oxopiperazin-2-yl)acetate 

Downstream Products

• 100-02-7 4-nitro-phenol 
• 5167-08-8 1,4-diaza-bicyclo[3.2.1]octane 
• 1308375-21-4 3-((R)-2-amino-2-phenyl-ethyl)-1-(2,6-difluoro-benzyl)-5-[3-(2-hydroxy-ethyl)-piperazin-1-yl]-6-methyl-1H-pyrimidine-2,4-dione 

Relevant articles and documents

TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed